Table 5.
Baseline characteristics for a cohort of NASH patients with biopsies at baseline and follow up.
| All patients | Fibrosis Improvement | Fibrosis no Change | Fibrosis worsening | P value | |
|---|---|---|---|---|---|
| Age | 50.1 ± 1.7 (41) | 50.8 ± 2.8 (15) | 49 ± 2.72 (16) | 50.5 ± 3.5 (10) | 0.886 |
| Gender M/F (%) | 13/41 ((32%) | 6/15 (40%) | 5/16 (31%) | 2/10 (20%) | 0.631 |
| Diabetes (%) | 15/41 (37%) | 3/15 (20%) | 8/16 (50%) | 4/10 (40%) | 0.228 |
| AST (U/L) (N) | 71.3 ± 8.1 (39) | 68.8 ± 9.9 (15) | 69.4 ± 17.47 (15) | 78.4 ± 12.9 (9) | 0.893 |
| ALT (U/L) (N) | 98.3 ± 9.2 (39) | 97.8 ± 11.0 (15) | 97.5 ± 10.0 (15) | 100.3 ± 10.9 (9) | 0.993 |
| ALP (U/L) (N) | 97.4 ± 4.4 (39) | 90.4 ± 7.7 (15) | 95.9 ± 6.2 (15) | 111.2 ± 9.3 (9) | 0.205 |
| total bilirubin (mg/dl) (N) | 0.58 ± 0.04 (40) | 0.74 ± 0.08 (15) | 0.48 ± 0.05 (15) | 0.51 ± 0.08 (9) | 0.038 |
| Albumin (g/dl) (N) | 4.6 ± 0.0 (40) | 4.6 ± 0.1 (15) | 4.5 ± 0.1 (15) | 4.6 ± 0.1 (9) | 0.867 |
| Fibrosis stage (N) | 1.7 ± 0.2 (41) | 1.9 ± 0.2 (15) | 1.6 ± 0.2 (16) | 1.5 ± 0.2 (10) | 0.321 |
| Steatosis grade (N) | 1.8 ± 0.1 (41) | 1.8 ± 0.2 (15) | 1.8 ± 0.1 (16) | 1.9 ± 0.3 (10) | 0.897 |
| Lobular inflammation grade (N) | 1.2 ± 0.1 (41) | 1.3 ± 0.2 (15) | 1.1 ± 0.1 (16) | 1.2 ± 0.1 (10) | 0.581 |
| Hepatocellular Ballooning grade (N) | 1.2 ± 0.2 (41) | 1.1 ± 0.2 (15) | 1.1 ± 0.2 (16) | 1.1 ± 0.2 (10) | 0.867 |
| biopsy interval (year) (N) | 3.4 ± 0.3 (41) | 3.5 ± 0.5 (15) | 3.2 ± 0.4 (16) | 3.5 ± 0.4 (10) | 0.878 |
Values are Mean ± standard error of mean. p values were generated by Anova analysis.